In 2010, the American Heart Association defined a novel construct of cardiovascular health
to promote a paradigm shift from a focus solely on disease treatment to one inclusive of …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Background Bempedoic acid, an ATP citrate lyase inhibitor, reduces low-density lipoprotein
(LDL) cholesterol levels and is associated with a low incidence of muscle-related adverse …

Abstract Aim The “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic
Disease” provides recommendations to guide clinicians in the diagnosis, genetic evaluation …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

The current and long-term health of 14.4 million children and adolescents is affected by
obesity, 1, 2 making it one of the most common pediatric chronic diseases. 3–5 Long …

Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …